Identification of Mycoplasma pneumoniae -associated pneumonia cases among hospitalized patients using CLART® microarray technology.
| Autor: | Tjoa E; Department of Microbiology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia., Joon S; School of Biotechnology, Jawaharlal Nehru University, New Delhi, India., Moehario LH; Department of Microbiology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia., Loe L; Department of Internal Medicine, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia., Pangalila FJV; Internal Medicine Department, Faculty of Medicine, Universitas Tarumanagara (UNTAR), Jakarta, Indonesia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of international medical research [J Int Med Res] 2022 Sep; Vol. 50 (9), pp. 3000605221123678. |
| DOI: | 10.1177/03000605221123678 |
| Abstrakt: | Objectives: Community-acquired pneumonia (CAP) is a global health condition that affects populations from all age groups. The laboratory identification of Mycoplasma pneumoniae as a causative agent of CAP is challenging because of its atypical and fastidious nature. Therefore, this study assessed the diagnostic potential of PneumoCLART bacteria® in identifying M. pneumoniae as a causative agent of pneumonia in hospitalized adults. Methods: This prospective study used a cross-sectional approach to assess the diagnostic potential of PneumoCLART bacteria® for detecting M. pneumoniae in sputum samples procured from 27 patients with pneumonia who required hospitalization. Results: The PneumoCLART bacteria® results illustrated that 7 of 27 patients with pneumonia were positive for M. pneumoniae (26%). However, the quality of sputum varied among the M. pneumoniae -positive and M. pneumoniae -negative samples. Fifty percent of the specimens obtained from patients positive for M. pneumoniae were saliva-contaminated and unsuitable for analysis. Conclusions: Because the leukocyte count was low and sputum specimens were saliva-contaminated, these findings require further validation to prove the utility of CLART® microarray technology for the identification of M. pneumoniae in pneumonia-positive patients. Conclusively, this prospective study included a small number of clinical samples, which likely affected its outcomes. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|